Diamyd Medical strengthens presence at scientific conferences
Diamyd Medical, represented by CEO Ulf Hannelius, has been elected to present a scientific poster at the American Society of Human Genetics (ASHG) conference to be held as a digital event on October 18 to October 22, 2021. The poster details the design of a pivotal genetic precision medicine trial based on findings from a large-scale meta-analysis encompassing more than 600 individuals with type 1 diabetes that have participated in clinical trials with the diabetes vaccine Diamyd[®] (GAD-alum).“There is a notably increasing interest from the scientifc community regarding our genetic